Abciximab prevents ischemic complications during angioplasty
The EPILOG Trial
Matthew T. Roe, MD
Department of Cardiology, Cleveland Clinic
David J. Moliterno, MD
Department of Cardiology, Cleveland Clinic; medical director, angiographic core laboratory, EPILOG trial
Address: David J. Moliterno, MD, Department of Cardiology, F25, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195
The EPILOG trial showed that the platelet glycoprotein IIb/IIIa inhibitor abciximab, together with heparin in a low, weight-adjusted dose, markedly reduced the risk of acute ischemic complications during percutaneous coronary revascularization, without increasing the risk of hemorrhage.